🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. The placebo product consists of a soft capsule similar to the ones containing the active substance, VESSEL® 250 ULS capsule molli

    Fondazione Telethon ETS

    Prevention of recurrence after a first episode of Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  2. The placebo product is manufactured to visually match the corresponding FDY-5301 injection drug product. It is formulated to match a standard saline solution comprised of Sodium Chloride and Water for Injection.

    Lacuna Pharma Pty Ltd

    Anterior ST-Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  3. The placebo tablet composition is: Collodial silicone dioxide, Magnesium stearate, Carmellose sodium, Cellulosa powder. Appearance and size will be the same for active and placebo., Trombyl 160 mg tabletter

    The George Institute

    Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

    phase 3 small molecule active

    1 trial

  4. Tildrakizumab Placebo Solution for Injection, TILDRAKIZUMAB

    Lacuna Pharma Pty Ltd

    Moderate to Severe Genital Psoriasis

    phase 3 small molecule active

    1 trial

  5. Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab

    Lacuna Pharma Pty Ltd

    Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis

    phase 3 small molecule active

    1 trial

  6. Tinlarebant 5 mg´s matching Placebo, LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Stargardt Disease

    phase 3 small molecule active

    1 trial

  7. Tiragolumab Placebo, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab, Tecentriq Placebo

    Hoffmann-La Roche

    Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  8. Tiragolumab, Placebo Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  9. Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period)

    Rare Thyroid Therapeutics International AB

    Monocarboxylate Transporter 8 (MCT8) deficiency

    phase 3 small molecule active

    1 trial

  10. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Placebo to match LY3298176 injection

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  11. Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  12. Tozorakimab, -, SALBUTAMOL, Tozorakimab-placebo

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  13. Tozorakimab, Tozorakimab-placebo

    AstraZeneca AB

    Severe viral lung infections

    phase 3 small molecule active

    1 trial

  14. Tozorakimab-placebo, Tozorakimab, SALBUTAMOL

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  15. Trazimera 420 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion, VINORELBINE ARROW 10 mg/ml, solution à diluer pour perfusion, TherO2-01S22, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Placebo syrup, Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    metastatic breast cancer

    phase 3 small molecule active

    1 trial

  16. Treprostinil, The Placebo Nebuliser Solution is a solution dosage form for nebulisation identical to Treprostinil Nebuliser Solution drug product except for the absence of the treprostinil drug substance.

    United Therapeutics Europe Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  17. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)

    phase 3 small molecule active

    1 trial

  18. Troriluzole, Placebo for BHV-4157 capsules, 100mg, 140mg, Troriluzole

    Lacuna Pharma Pty Ltd

    Obsessive Compulsive Disorder

    phase 3 small molecule active

    1 trial

  19. UI022 or UI023 and co-administration of matching placebo

    United Therapeutics Europe Ltd

    Peripheral Arterial Disease

    phase 3 small molecule completed

    1 trial

  20. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion, Anti C5 Complement mAb Placebo

    Alexion Europe SAS

    Delayed Graft Function after Kidney Transplantation

    phase 3 small molecule active

    1 trial

  21. Upadacitinib Placebo, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    non-segmental vitiligo

    phase 3 small molecule active

    1 trial

  22. Upadacitinib Placebo, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Alopecia Areata

    phase 3 small molecule active

    1 trial

  23. Upadacitinib, Placebo for upadacitinib tablet, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  24. VALACICLOVIR ARROW 500 mg, comprimé pelliculé sécable, PREVYMIS PLACEBO, VALACICLOVIR PLACEBO, PREVYMIS 240 mg film-coated tablets

    Pari Pharma GmbH

    Diseases [C] - Virus Diseases [C02]

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources